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Abstract
The finding that molt-inhibiting hormone (MIH) regulates vitellogenesis in the hepatopancreas of
mature Callinectes sapidus females, raised the need for the characterization of its mode of action.
Using classical radioligand binding assays, we located specific, saturable, and non-cooperative
binding sites for MIH in the Y-organs of juveniles (J-YO) and in the hepatopancreas of vitellogenic
adult females. MIH binding to the hepatopancreas membranes had an affinity 77 times lower than
that of juvenile YO membranes (KD values: 3.22 × 10-8 and 4.19 × 10-10 M/mg protein, respectively).
The number of maximum binding sites (BMAX) was approximately two times higher in the
hepatopancreas than in the YO (BMAX values: 9.24 × 10-9 and 4.8 × 10-9 M/mg protein, respectively).
Furthermore, MIH binding site number in the hepatopancreas was dependent on ovarian stage and
was twice as high at stage 3 than at stages 2 and 1. SDS-PAGE separation of [125I] MIH or [125I]
crustacean hyperglycemic hormone (CHH) crosslinked to the specific binding sites in the
membranes of the J-YO and hepatopancreas suggests a molecular weight of ~51 kDa for a MIH
receptor in both tissues and a molecular weight of ~61 kDa for a CHH receptor in the
hepatopancreas. The use of an in vitro incubation of hepatopancreas fragments suggests that MIH
probably utilizes cAMP as a second messenger in this tissue, as cAMP levels increased in response
to MIH. Additionally, 8-Bromo-cAMP mimicked the effects of MIH on vitellogenin (VtG) mRNA and
heterogeneous nuclear (hn) VtG RNA levels. The results imply that the functions of MIH in the
regulation of molt and vitellogenesis are mediated through tissue specific receptors with different
kinetics and signal transduction. MIH ability to regulate vitellogenesis is associated with the
appearance of MIH specific membrane binding sites in the hepatopancreas upon pubertal/final molt.
Background
The X-organ in the eyestalks of crustaceans produces a
family of crustacean hyperglycemic hormone (CHH) neu-
ropeptides unique to arthropods. The CHH family mem-
bers in crustaceans (CHH, molt-inhibiting hormone
(MIH), mandibular organ-inhibiting hormone (MOIH),
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and gonad/vitellogenesis-inhibiting hormone (GIH/
VIH)), are involved in the regulation of a variety of phys-
iological processes [1-6]. It has been established that indi-
vidual CHHs are multifunctional, having specific binding
sites in multiple target tissues [7,8]. More specifically, in
addition to its primary hyperglycemic action [9], CHH
inhibits ecdysteroidogenesis [10]; regulates water uptake
during ecdysis [6]; and inhibits methionine incorporation
in ovarian fragments, in vitro [11]. It was recently demon-
strated that in addition to its traditional molt inhibiting
role, MIH is also involved in the regulation of vitellogen-
esis in the mature female Callinectes sapidus [12] and in
Metapenaeus ensis [13]. Since specific hormonal functions
are accomplished by neuropeptides and their correspond-
ing receptors [14], efforts have been made to identify and
characterize the CHH neuropeptides family of receptors
by means of binding kinetics [15-18], signal transduction
[15,19-27], and cloning studies [28-31]. However, to
date, the mechanisms by which the multiple functionality
of these neuropeptides is being executed, are not fully
understood.
MIH exerts its molt inhibiting activity on the Y-organs
(YO) through the suppression of ecdysteroid synthesis
and secretion [32-36] via the down-regulation of protein
synthesis [19,22]. It has been reported that MIH binds
exclusively to a YO membrane receptor with high affinity
in a specific, displaceable, and saturable manner [16,17].
Attempts to define the mechanism of MIH signaling
revealed changes in YO responsiveness throughout a molt
cycle [23,37,38]. While MIH titers in the hemolymph and
the number of binding sites of MIH in the YO of Carcinus
maenas remained unchanged throughout a molt cycle, the
level of cGMP responding to MIH in this tissue was greater
at intermolt than at premolt stages [38]. This was further
supported by the finding in Procambarus clarkii that phos-
phodiesterase activity in the YO at intermolt is markedly
low, resulting in an extended cyclic nucleotide life span
and in turn, higher levels [23].
It has been reported that MIH and CHH act via cGMP as a
primary second messenger [15,23,26-28,37-39] although
the involvement of cAMP, or both cAMP and cGMP [25]
was also suggested. The large increase in cGMP produc-
tion in the YO in response to MIH of C. sapidus [23] and
the stimulation of cGMP in many tissues by CHH in C.
maenas [15] have implicated a potential involvement of
nitric oxide (NO-), soluble guanylate cyclases [20], or
membrane guanylate cyclase type receptors [28,31,40].
However, the structural characterization of a receptor for
the CHH family of neuropeptides has not yet been eluci-
dated in crustaceans nor in insects [41].
Ovarian development in crustaceans is controlled by neu-
rohormones [42,43]. The inhibition of vitellogenesis by
sinus gland factors is described in many species [3,44,45],
while gonad stimulatory activity originates in the eyestalk,
brain, and thoracic ganglia [13,46,47]. Overall, it appears
that inhibition and stimulation are mediated by neu-
ropeptides of the CHH family [13,44,45,47-53], with one
exception that attributes the stimulatory action to a small
peptide of 1000–2000 Da [54]. Further, a study in Marsu-
penaeus japonicus suggests that vitellogenic inhibition is
modulated by Ca2+, cAMP, cGMP, and protein kinase C
[24]. Much work is still required, however, to define the
exact second messengers and the signal transduction path-
ways downstream of the neuropeptides that control vitel-
logenesis in crustaceans.
We have recently reported that MIH levels in the hemol-
ymph of female C. sapidus are correlated with vitellogenic
activity, i.e., higher at mid-vitellogenic than at previtello-
genic stage. Furthermore, by the incubation of hepatopan-
creas fragments in vitro, we demonstrated that MIH acts
directly in an ovarian stage dependent manner on the
hepatopancreas where it stimulates mRNA, heterogene-
ous nuclear RNA of vitellogenin (hnVtG RNA = the newly
transcribed yet unprocessed nuclear VtG mRNA) and VtG
translation [12]. Consequently, we proposed that MIH
has a regulatory role in vitellogenesis of the adult female,
in addition to its prototypical molt inhibitory function.
This fact imposed a re-examination of the accepted para-
digm that MIH binds exclusively to the membranes of YO
[16,17] by verifying the presence of a specific receptor for
MIH in the hepatopancreas of the female C. sapidus.
In the current study, we employed a classical radioligand
binding assay to 1) locate and characterize specific bind-
ing sites of MIH in hepatopancreatic membranes of vitel-
logenic females, and 2) determine the molecular weights
of MIH receptors in the membranes of hepatopancreas
and the YO. In addition, we also examined the second
messenger of MIH in hepatopancreas using an in vitro
incubation assay and radioimmunoassays (RIA). The YO
responded to MIH by elevating cGMP levels, while the
hepatopancreas responded by increasing cAMP produc-
tion. Altogether, our results indicate that MIH acts on the
YO and the hepatopancreas via a tissue specific receptor.
Results
MIH binding to the YO membranes
To determine the maximal number of binding sites of
MIH in the membranes of the YO, 50 μg of membrane
proteins were incubated with [125I] MIH from 0.15 to 12.3
nM. The non-specific binding was determined using
recombinant MIH (rMIH) due to the limited amount of
native MIH (nMIH). The rMIH was as potent as nMIH in
cGMP production in the YO in vitro (unpublished results)
and produced the same EC50 value in a specific RIA using
antibody raised against rMIH [12]. As shown in Fig. 1A,Saline Systems 2009, 5:6 http://www.salinesystems.org/content/5/1/6
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the binding sites were saturable with a KD value of 4.19 ×
10-10 M/mg protein and a BMAX value of 4.8 × 10-9 M/mg
protein. Labeled and bound MIH was displaced with cold
rMIH [12] at concentrations ranging from 24.4 pM to 10
nM (Fig. 1B) with an EC50 value of 0.67 nM. A displace-
ment study was carried out on YO membranes using cold
nMIH, resulting in a similar EC50 value of 0.66 nM. The
non-specific binding in these experiments was ~20–30%
of the total binding.
MIH binding to the hepatopancreas membranes
Membranes (100 μg) of hepatopancreas at ovarian stages
1 to 3 and gills, abdominal muscle, YO and ovaries that
were pooled from five females at each ovarian stage were
incubated with 0.4 pmol [125I] MIH (263,000 DPM) with
or without an excess of 20 pmol unlabelled rMIH. Hepat-
opancreas membranes prepared from five adult males and
from juveniles were also tested, with juvenile YO (J-YO)
membranes serving as a reference control. Specific bind-
ing of MIH was found only in mature female hepatopan-
creas among the tissues tested. MIH binding at ovarian
stage 3 was two times higher than in stage 1 and com-
prised ~40% of the J-YO control (Fig. 2A). MIH binding to
the YO of mature females at stage 3 was equal to that of
juveniles (not shown in the figure). The same membranes
were tested for [125I] CHH binding by incubating 100 μg
with 0.12 pmol [125I] CHH (~182,000 DPM) and unla-
beled native CHH at 20 pmol for non-specific binding.
No significant difference in CHH binding to the hepato-
pancreas was observed between the different ovarian
stages, however, CHH binding to juvenile hepatopancreas
was two times higher than to J-YO and the other tissues.
Saturation curve (A) and displacement curve (B) of [125I] MIH  to the membranes of YO of juvenile C. sapdius Figure 1
Saturation curve (A) and displacement curve (B) of 
[125I] MIH to the membranes of YO of juvenile C. 
sapdius. Bound [125I] MIH was displaced with unlabelled 
rMIH. The data are presented as mean ± SEM of the tripli-
cates.
MIH specifically binds to membranes of mature female hepat- opancreas with higher binding at mid-vitellogenic stage than  pre-vitellogenic Figure 2
MIH specifically binds to membranes of mature 
female hepatopancreas with higher binding at mid-
vitellogenic stage than pre-vitellogenic. A) Specific 
binding of [125I] MIH to various tissue membranes of vitello-
genic females and YO and hepatopancreas of juveniles. B) 
Specific binding of [125I] CHH to the same membranes. All 
membranes were prepared from five animals, except for J- 
YO membranes that were prepared from 700 intermolt ani-
mals. F, Females; M, Males; J, juveniles; HP, hepatopancreas; 
1, 2, and 3 refer to the ovarian stages; F-ovary- ovarian mem-
brane of females at ovarian stage 3. Results are presented as 
mean ± SEM of the triplicates as % of the J-YO. The alphabet-
ical letters show the significant differences at P < 0.05.
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The ovaries exhibited a binding 20 times lower than J-YO
(Fig. 2B).
A saturation curve was obtained by incubating 0.75 to 60
nM [125I] MIH with 100 μg hepatopancreas membranes of
ovarian stage 3 females (Fig. 3A). The calculated KD and
BMAX values were 3.22 × 10-8 M/mg protein and 9.24 × 10-
9 M/mg protein, respectively. Displacement studies were
conducted using 0.04 nM – 100 nM unlabeled rMIH as
well as 12.5 – 100 nM native CHH. rMIH competed with
[125I] MIH on the binding sites with an EC50 value of
17.35 nM, whereas CHH showed no displacement of
[125I] MIH (Fig. 3B). The non-specific binding in these
studies was ~40% for MIH and ~30% for CHH.
The plots obtained for MIH binding to the membranes of
the J-YO and hepatopancreas were overlaid in order to
demonstrate the difference in the affinities and the
number of maximal binding sites (Fig. 4A and 4B). Calcu-
lated KD values were ~77 times greater in the J-YO than
female hepatopancreas: 4.19 × 10-10 and 3.22 × 10-8 M/mg
protein, respectively. Values of BMAX were 9.24 × 10-9 M/
mg protein for hepatopancreas and 4.80 × 10-9 M/mg pro-
tein for J-YO.
MIH and CHH effects on cAMP and cGMP levels in the 
hepatopancreas of vitellogenic females, in vitro
The effects of MIH and CHH on levels of cAMP and cGMP
production were tested in vitro in hepatopancreas frag-
ments of vitellogenic females at ovarian early stage 2 (E2).
As presented in Figs. 5A and 5B, CHH (20 nM) resulted in
a 16 times increase in the levels of cGMP production
(from 2 to 32 pmol/mg protein), while MIH at 2 nM had
no effect. Cyclic AMP levels did not change with CHH, but
increased by 50% in response to 2 nM MIH (from 22 to
33 pmol/mg protein, N = 4), compared to the control
which received 1 mM isobutylmethylxanthine (IBMX)
alone (Fig. 5B).
Kinetic binding studies of [125I] MIH to the hepatopancreas  membranes of female C. sapidus at ovarian stage 3 demon- strate receptor/ligand typical and specific binding Figure 3
Kinetic binding studies of [125I] MIH to the hepato-
pancreas membranes of female C. sapidus at ovarian 
stage 3 demonstrate receptor/ligand typical and spe-
cific binding. Five membrane preparations were pooled and 
tested. A) Saturation curve; B) Displacement curve. [125I] 
MIH binding sites were displaced with unlabelled rMIH 
(closed circles) or unlabelled CHH (open circles). The data 
are presented as mean ± SEM of the triplicates.
MIH binding to female hepatopancreas membranes is charac- terized by a lower affinity and higher density compared to  juvenile YO Figure 4
MIH binding to female hepatopancreas membranes 
is characterized by a lower affinity and higher density 
compared to juvenile YO. Overlay of the curves of satu-
ration (A) and displacement (B) of [125I] MIH binding to YO 
and female hepatopancreas membranes to emphasize the dif-
ferences in values of KD and BMAX between these tissues. YO, 
closed circles; hepatopancreas, open circles.Saline Systems 2009, 5:6 http://www.salinesystems.org/content/5/1/6
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The effects of cyclic nucleotide analogs on VtG 
transcriptions: hnVtG RNA and VtG mRNA
The incubation of hepatopancreas fragments at E2 with
the membrane permeable 8-Bromo-cAMP resulted in a
36% increase in the level of hnVtG RNA, while 8-Bromo-
cGMP had no effect (Fig. 6). VtG mRNA in the hepatopan-
creas at E2 decreased to 50% compared to the control with
8-Bromo-cAMP, whereas it remained constant with 8-
Bromo-cGMP (Fig. 6).
Molecular weights of putative MIH receptors in the 
membranes of the YO and hepatopancreas of vitellogenic 
female
YO and hepatopancreas membranes that were preincu-
bated with [125I] MIH or hepatopancreas with [125I] CHH
and crosslinked with disuccinimidyl suberate (DSS), were
separated on SDS-PAGE and the signal was detected using
a phosphorimager. Two bands were observed for each
membrane: a lower one at the expected size of MIH
(9070.9 Da) or CHH (8478.1 Da) [55]; and, a second
higher band at an estimated size of ~60 kDa for MIH (Figs.
7A and 7B). Binding of [125I] CHH to hepatopancreas
membranes revealed a signal at a molecular weight of ~70
kDa (Fig. 7B). Assuming a binding ratio of 1 to 1 (ligand:
receptor), the estimated size for the MIH receptor in both
the YO and the hepatopancreas is ~51 kDa and ~61 kDa
for the CHH receptor in the hepatopancreas.
Discussion
Based on our recent finding that MIH acts as a vitellogen-
esis stimulant in addition to its molt inhibitory function
[12], we demonstrated in the current study the presence of
specific binding sites for MIH in the J-YO membranes as
well as novel binding sites in hepatopancreatic mem-
branes of vitellogenic female C. sapidus. Kinetic studies
revealed a specific, saturable, and non-cooperative bind-
ing indicative of a receptor-ligand interaction in both tis-
sues, with differences in the affinity and density of the
receptors between the two tissues. In addition, we have
shown by crosslinking [125I] MIH to its receptor in the YO
and hepatopancreas that the receptors are proteins with
an estimated molecular weight of ~51 kDa.
The radioligand receptor assays revealed that the presence
of MIH specific binding sites in the hepatopancreas is
found only in adult females and is vitellogenic stage- spe-
cific. Bound MIH in the hepatopancreas was specifically
displaced by recombinant MIH (rMIH), but not by CHH
(Fig. 3B). Moreover, MIH binding capacity in the hepato-
pancreas increased as ovarian stage advanced from 1 to 3,
CHH induces cGMP and MIH induces cAMP production in  female hepatopancreas fragments Figure 5
CHH induces cGMP and MIH induces cAMP produc-
tion in female hepatopancreas fragments. In vitro: A) 
cGMP; B) cAMP. Hepatopancreas fragments were incubated 
with 20 nM CHH or 2 nM MIH. The results are presented as 
mean ± SEM (N = 4). *, P ≤ 0.05; **, P ≤ 0.01.
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cGMP analog mimics the effects of CHH and cAMP analog  mimics the effect of MIH on VtG mRNA and hnVtG RNA in  the hepatopancreas fragments of stage E2 females, respec- tively Figure 6
cGMP analog mimics the effects of CHH and cAMP 
analog mimics the effect of MIH on VtG mRNA and 
hnVtG RNA in the hepatopancreas fragments of stage 
E2 females, respectively. Hepatopancreas fragments were 
incubated with 10 μM 8-Bromo- cGMP or 8-Bromo- cAMP 
followed by QPCR analysis to detect changes in hnVtG 
(Black) and VtG mRNA (Grey). The results are presented as 
mean ± SEM of % of control (N = 4). *, P ≤ 0.05; **, P ≤ 0.01.Saline Systems 2009, 5:6 http://www.salinesystems.org/content/5/1/6
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reaching ~40% of that of the J-YO binding, reflecting BMAX
values (4.8 × 10-9 and 9.24 × 10-9 M/mg protein of J-YO
and hepatopancreas, respectively). The ovarian stage
dependent increase of MIH binding in the hepatopan-
creas may be responsible for the ovarian stage dependent
MIH effect on vitellogenesis[12]. In contrast, CHH bind-
ing was ubiquitous in the tissues tested except for ovary,
as has been described in C. maenas [15]. Moreover, CHH
binding in the hepatopancreas did not differ significantly
between ovarian stages and sex (Fig. 2B). The BMAX value
for CHH binding in the hepatopancreas of C. sapidus was
3.67 × 10-10 M/mg protein [18], similar to the value of
3.28 × 10-10 M/mg protein obtained for hepatopancreas of
C. maenas [15]. This suggests that at ovarian stage 3, the
number of MIH receptors in the hepatopancreas is the
highest ever reported in the binding studies of the family
of CHH neuropeptides, being 30 times higher than that of
the CHH receptor. This high density of MIH receptors in
hepatopancreas may cause higher non-specific binding
than in the J-YO, as shown in Fig, 4B and Figs 7A and 7B.
When considering the difference in size of the tissues
between the J-YO (~20 mg) and the hepatopancreas (~7
g) in adult females, the total number of MIH binding sites
can easily be ~700 times higher in the hepatopancreas
than in the YO.
As shown in Fig. 4, KD values of MIH binding sites in the
J-YO and female hepatopancreas membranes were signif-
icantly different: 4.19 × 10-10 and 3.22 × 10-8 M/mg pro-
tein, respectively. These values indicate that the affinity of
the MIH receptor in the hepatopancreas is 77 times lower
than that of the J-YO. Similar to what has been reported
for C. maenas, CHH binding sites in the YO and hepato-
pancreas membranes had calculated KD values of 1.82 ×
10-9 and 6 × 10-10 M/mg protein, respectively [17]. These
affinities were comparable to those obtained for MIH
binding sites in the J-YO (4.19 × 10-10 M/mg protein), all
in the 0.1 nM/mg protein range. Thus, it seems that MIH
binding sites in the hepatopancreas have the lowest affin-
ity to its ligand among those of CHH neuropeptides char-
acterized thus far. The low affinity of the hepatopancreas
receptor may require high circulating titers of MIH, with
concentrations ranging from 0.01–20 nM for binding
(Fig. 3A). The level of MIH at ovarian stage 3 was ~0.02
nM [12], which was slightly higher than that of intermolt
(~0.015 nM). Taken together, MIH receptor in the hepat-
opancreas is featured by low affinity-high binding capac-
ity to its ligand (Fig. 4). The presence of different receptors
for a ligand with different binding kinetics is well known
for steroid receptors such as glucocorticoid receptor [56],
peptides like gonadotropin-releasing hormone receptors
[57], and polypeptide receptors such as prolactin receptor
[58].
To determine whether the MIH signals through cGMP as
a second messenger in the hepatopancreas as it does in the
YO [38], we measured in vitro production of cyclic nucle-
otides in hepatopancreas fragments in the presence of 2
nM MIH or 20 nM CHH, which are effective doses in vitel-
logenesis [12]. As expected, intracellular cGMP levels in
the hepatopancreas increased by 16 fold in response to
CHH, but did not change with MIH treatment (Fig. 5A).
On the other hand, cAMP levels significantly increased by
50% with MIH, but did not change with CHH treatment
(Fig. 5B). The difference in the magnitude of response in
the increase of cGMP (by CHH) compared to cAMP (by
MIH) may be due to different basal levels: cAMP, 20
pmol/mg protein; cGMP, < 1 pmol/mg protein. Hepato-
pancreas fragments incubated with 8- Bromo-cAMP aug-
mented hnVtG RNA levels, while 8-Bromo-cGMP had no
effect (Fig. 6). These findings are congruent with our pre-
vious results of no effect of CHH and the stimulatory
effect of MIH on hnVtG transcription at stage E2 [12].
Moreover, the membrane permeable 8-Bromo-cAMP and
8-Bromo-cGMP mimicked the effects of MIH and CHH,
respectively, on VtG  mRNA.  VtG  mRNA significantly
decreased by 60% with MIH and 20% with CHH in hepat-
opancreas fragments of ovarian stage E2 females[12].
The results obtained from the crosslinking studies showed
that the complexes of MIH and its receptor in both the J-
Binding sites of [125I] MIH in the membranes of female's  hepatopancreas and juvenile YO have a similar molecular  mass of ~51 kDa, which is different from that of [125I] CHH  in the hepatopancreas Figure 7
Binding sites of [125I] MIH in the membranes of 
female's hepatopancreas and juvenile YO have a sim-
ilar molecular mass of ~51 kDa, which is different 
from that of [125I] CHH in the hepatopancreas. A) J-
YO (100 μg); B) female hepatopancreas at ovarian stage 3 
(200 μg). Membranes were incubated without (total binding, 
Tb) or with unlabeled MIH or CHH in an excess of 1 or 10 
pmol, specified at the top of the lane. YO membranes were 
resolved on a 4–15% SDS-PAGE and hepatopancreas mem-
branes on a 10% SDS-PAGE. Labeled ligand and receptor 
complexes are indicated with arrows.Saline Systems 2009, 5:6 http://www.salinesystems.org/content/5/1/6
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YO and the hepatopancreas have an estimated size of ~60
kDa, resulting in a MW of ~51 kDa for the receptor, which
is different from that of the CHH receptor in the hepato-
pancreas (MW ~61 kDa). Together with the second mes-
senger data, this suggests that there is a tissue specific type
of membrane receptor for MIH, since only one band
appeared in the autoradiogram in addition to the
unbound neuropeptides (Figs. 7A and 7B). A similar
study estimated the size of the MIH receptor in the YO of
the kuruma prawn as ~70 kDa [16]. Such a difference may
lie in the difference in species.
The increase in intracellular cAMP in the hepatopancreas
caused by MIH opposes the possibility that the receptor is
a guanylate cyclase, and instead favors the option of a G
protein – coupled receptor (GPCR) that acts through a
GTP binding protein to activate a nucleotide cyclase. This
agrees with the calculated MW of the hepatopancreas
putative MIH receptor of ~51 kDa, which is different from
the typical membrane guanylate cyclase having a MW of
120–140 kDa [59]. In addition, the similarity in the MWs
of MIH binding sites on the YO and hepatopancreas indi-
cates that both MIH receptors may be GPCRs, however,
each form may activate a different signaling pathway. A
possible scenario is that the hepatopancreas MIH receptor
activates the αs subunit of the G protein-adenylyl cyclase,
while the YO isoform activates soluble guanylyl cyclase
through Ca2+and NO- initiated by an increase in cAMP.
Support for the latter option is found in a study reporting
that incubation of the YO of C. maenas and P. clarkii at
premolt stage with MIH resulted in a sustained 60 times
increase in cGMP levels, and also a short, transient two
fold increase in cAMP [23,25]. In addition, it was sug-
gested that nitric oxide synthase and NO- are possibly
involved in the MIH signaling in the YO of the land crab,
Gecarcinus lateralis [20,60]. In this regard, the involvement
of trimeric G proteins in inhibition of protein synthesis in
the YO of C. sapidus, was proposed [29]. Overall, the two
suggested signaling pathways may involve a complex net-
work of interactions and will require more rigorous inves-
tigations.
It was speculated that an extensive gene duplication event
may have occurred to produce multiple CHH isoforms
which may show tissue specific expression [61]. Similarly,
receptors including the GPCR family members are
believed to propagate by gene duplication from a com-
mon ancestor [62]. This includes odorant receptors [63],
hormone receptors like growth hormone [64], gonado-
trophins [65], gonadotrophin releasing hormones [66]
and many more. Although the sequences of the MIH
receptors in the current study are still unknown, these two
receptors may possibly be products of gene duplication
and share a high degree of structure similarity.
It is generally recognized that individual hormones can
elicit several diverse responses in different organs and tis-
sues, as well as in individual cells [14]. Several mecha-
nisms may be involved in mediating the different signals
such as 1) pulses and micropulses (frequency of changes
of hormone circulation or endogenous concentrations);
2) changes in the activities of hormone-converting
enzymes; 3) selective activation of each receptor type, sub-
type, and isoform; 4) changes in receptors, which may
activate and suppress different signaling pathways (e.g.
phosphorylation, dimerization); and 5) activation and
suppression of different nuclear transcription processes
[14]. The MIH receptor in the mature female's hepatopan-
creas is clearly different from the one present in the YO in
terms of its time of appearance/functionality, its binding
kinetics, and signal transduction. Thus, it fits some of the
mechanisms mentioned above and provides a possible
model for multi-functionality of the CHH neuropeptide
family, which is based upon a diverse spatial and tempo-
ral expression, binding kinetics and signal transduction
pathway. Based on this finding, we propose that some
pleiotropicity of the CHH neuropeptide family might be
mediated by multiple receptor forms: each form executes
a different function.
Conclusion
In this study, we demonstrated the presence of novel spe-
cific MIH binding sites in the hepatopancreas of the
mature female C. sapidus that are involved in MIH regula-
tion of vitellogenesis. MIH action in the hepatopancreas is
probably mediated by cAMP, unlike the YO counterpart
that utilizes cGMP as a second messenger. Our result sug-
gests that in the female C. sapidus, the antagonism
between molting and reproduction is mediated by MIH
that acquires a vitellogenesis stimulating function in addi-
tion to its traditional molt-inhibitory action. This new
role is obtained through the expression of abundant MIH
specific receptors in the hepatopancreas of the adult
females. To our knowledge, this is the first description of
an endocrine regulation mechanism of the antagonism
between molting and reproduction in a crustacean spe-
cies. As we proposed in Zmora et al. [12], this may occur
in other crustaceans, particularly in those who share a
similar life cycle with the female C. sapidus (i.e., a terminal
molt upon puberty). It will be interesting to further exam-
ine how the two MIH receptors structurally differ and
determine the specific timing and cues for the hepatopan-
creas MIH receptor appearance or activation.
Methods
Animals
Juvenile blue crabs at intermolt stage (carapace width 5–
7.5 cm) were collected by using a seine or a trot line from
the eastern shore of the Chesapeake Bay [67]. Mature
females obtained from a local waterman were transferredSaline Systems 2009, 5:6 http://www.salinesystems.org/content/5/1/6
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in aerated water and acclimated for 2 to 3 days without
feeding in a 4.5 cubic meter re-circulating tank at ambient
conditions. Tissue collection was carried out as described
[68]. The tissues were dissected, rinsed in ice-cold crusta-
cean saline and stored at -80°C until further processing.
Purification and quantification of native CHH, native 
MIH, and recombinant MIH
Neuropeptides of the sinus glands (SG) and rMIH were
purified using RP-HPLC as described [17]. Amino acid
analyses were carried out for the quantification of the
purified native MIH, native CHH and rMIH using o-
phthalaldehyde pre-column derivatization method as
outlined [17].
Radioligand binding assays
Preparation of membranes
Membranes were prepared from ~700 YO's collected from
juvenile C. sapidus (J-YO, 5–7.5 cm carapace width) at
intermolt stage (C4) by following the method as
described [17]. Hepatopancreas membranes were pre-
pared from individual females or males, using ~1 g tissue.
Each hepatopancreas or 700 pooled YO were homoge-
nized in 20 ml ice-cold homogenization buffer (140 mM
NaCl, 300 mM sucrose, 10 mM HEPES, and 10 mM ben-
zamidine (Sigma), pH 7.4) using an Ultra Torax homoge-
nizer. After an initial centrifugation at 1000 g for 5 min at
4°C, the supernatant was pelleted by centrifugation at
30,000 g for 30 min at 4°C. The pellet was washed in
washing buffer (140 mM NaCl and 10 mM HEPES, pH 7.4
without BSA) by repeating the previous centrifugation
step for 15 min and resuspending in the same buffer. Pro-
tein concentration was determined using a DC protein
quantification kit (BioRad) and the membranes were aliq-
uoted and stored at -80°C until further use.
MIH and CHH binding studies
Binding assays
Native [125I] MIH and native [125I] CHH were prepared
using the chloramine-T labeling method as described [17]
or using 1,3,4,6-tetrachloro-3alpha, 6alpha-diphenylglu-
coluril (iodogen) coated tubes (Pierce) according to the
manufacturer's instruction. [125I] MIH or [125I] CHH was
separated from free [125I] on a PD 10 column (GE Health-
care) as described [17]. Specific activities were approxi-
mately 300–500 Ci/mmol.
The MIH binding procedure was followed as stated [69].
Briefly, membranes were incubated in binding assay
buffer (washing buffer containing 1% BSA) with [125I]
MIH or [125I] CHH for 1 h at room temperature. For dis-
placement and non-specific binding, unlabeled native
CHH or recombinant MIH (rMIH) produced in S2 Dro-
sophila cells (Zmora et al. companion paper 1) was added
to the reaction. The membranes were then washed in
binding assay buffer and pelleted by centrifugation at
14,000 rpm for 5 min. The pellets were counted in a
gamma-counter (HP counter). Each assay was repeated
three or four times in triplicates.
The effects of MIH and CHH on the levels of cAMP and 
cGMP, in vitro
The hepatopancreas of vitellogenic females at stage E2 was
excised and washed in 10 volumes of ice-cold Medium
199 (osmolarity 960 mmol/kg, 0.1 mg/ml BSA and 1×
protease inhibitors cocktail for tissue culture (Sigma), pH
7.4) for 3 h on ice, with three media changes as described
[68]. Quantification of cAMP or cGMP in tissues using
RIAs followed the procedure as described [70]. In brief,
fragments of 10 mg each were incubated for 1 h at room
temperature in the presence of 2 nM MIH or 20 nM CHH
in 400 μl Medium199 medium containing 1 mM IBMX,
or only IBMX for the control. The tissues were then dis-
rupted by sonication (Branson) and centrifuged at 14,000
rpm for 10 min at 4°C. Supernatants (100 μl) were trans-
ferred to tubes containing 900 μl of 0.1 M acetate buffer
(pH 4.75) and immediately acetylated by the addition of
20 μl triethylamine (Sigma) and 10 μl acetic anhydride
(Sigma). Fifty or one hundred μl of acetylated samples
were subjected to cAMP and cGMP RIAs. The standards for
cAMP and cGMP in the range of 1–1000 fmol/tube were
treated the same as the samples. The final dilution of anti-
bodies was 1: 21,000 for cGMP and 1:4000 for cAMP.
2'-O-methyl ester cAMP or cGMP (0.3 nmol) (Sigma)
were iodinated with Na [125I] (Amersham) using the chlo-
ramine T method as described [70]. The iodinated mate-
rial was separated from free [125I] on a C18  Sep-Pak
cartridge (Waters) by elution with 40% isopropanol [71].
The calculated specific activities were approximately 500–
600 Ci/mmol.
The effects of membrane permeable analogues of cAMP 
and cGMP on vitellogenin gene expression, in vitro
Hepatopancreas tissue was washed as described above
and fragments of 10 mg each were incubated in 400 μl
Medium199 medium containing 10 μM 8-Bromo-cAMP
or 8-Bromo-cGMP (Alexis) for 1 or 6 h. RNA was extracted
and the levels of hnVtG RNA and VtG mRNA were deter-
mined using quantitative PCR analysis (QPCR) analysis as
described in Zmora et al. (companion paper 1).
Crosslinking [125I] MIH or [125I] CHH to their binding sites 
and visualization
Juvenile YO membranes (100 μg) were incubated with 0.4
pmol [125I] MIH (~263,000 DPM) for total binding or
with additional 1 or 10 pmol/100 μl unlabeled rMIH for
nonspecific binding. The membranes were then washed
twice with 1 ml ice-cold washing buffer by centrifugation
at 14,000 rpm for 10 min. The pellets were resuspendedSaline Systems 2009, 5:6 http://www.salinesystems.org/content/5/1/6
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in 100 μl buffer containing DSS (Pierce) at a final concen-
tration of 1 mM for 30 min at room temperature. The reac-
tion was then quenched by the addition of 15 μl of 1 M
Tris buffer (pH 7.4) for 15 min at room temperature and
centrifuged at 14,000 rpm for 5 min. The pelleted mem-
branes were resuspended in 1× SDS sample loading buffer
(Bio-Rad) and denatured for 5 min at 100°C. Proteins
were separated on a 4–15% SDS-PAGE and briefly stained
with Bio-Safe coomassie (Bio-Rad) for visualization. The
gel was then dried and exposed to a Phosphor-imager
screen for 2 h at room temperature and analyzed using a
Typhoon 9410 variable mode imager (Molecular Dynam-
ics).
As for hepatopancreas membranes, the conditions
described above were applied except that 200 μg of the
hepatopancreas membranes were incubated with 1 pmol
[125I] MIH (~657,000 DPM) with or without 10 pmol
cold MIH or 0.12 pmol [125I] CHH (182,500 DPM) and
10 pmol cold CHH for non-specific binding. After
crosslinking with 5 mM DSS, membranes were lysed by
adding 4% Triton X-100 for 10 min in binding buffer, fol-
lowed by dilution to 1% Triton X-100. The sample was
then immunoprecipitated with 4 μl MIH antiserum for 1
h at 4°C, followed by the addition of protein-A magnetic
beads (New England Biolabs) to the mixture and incu-
bated for an additional hour. Bound proteins were sepa-
rated via a magnet apparatus and eluted with 3× SDS
sample loading buffer. After heating at 70°C for 3 min,
the samples were run on a 10% SDS PAGE. The gel was
dried and analyzed as described above.
Statistical analysis
The results obtained from the radioligand binding studies
are presented for each experiment as the mean ± SEM of
the experimental replicates. The data obtained from
QPCR analysis and RIA are presented as mean ± SEM for
the separate experiments. The results were subjected to
GraphPad Instat 3 program analysis (Graphpad) and were
examined using one-way ANOVA followed by the Tukey-
Kramer multiple comparison test. In all cases, statistical
difference was accepted at P ≤ 0.05.
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